Study on 5-fluorouracil in Colorectal Cancer Patients
Author Information
Author(s): Jodrell D I, Stewart M, Aird R, Knowles G, Bowman A, Wall L, Cummings J, McLean C
Primary Institution: ICRF Medical Oncology Unit, University of Edinburgh
Hypothesis
Does protracted venous infusion of 5-fluorouracil lead to less variability in drug concentration and better outcomes in patients with advanced colorectal cancer?
Conclusion
The study found that variability in 5FU concentrations was less than previously reported, and there was no correlation between drug levels and treatment outcomes.
Supporting Evidence
- The response rate was 26% with 33% of patients having stable disease.
- Median survival for patients was 11 months.
- Hand–foot syndrome was the most common dose-limiting toxicity.
- Variability in 5FU concentrations was considerably less than previously reported.
Takeaway
Doctors studied a medicine called 5FU to see how it works in cancer patients. They found that the amount of medicine in the body was more stable than before, but it didn't help predict how well the treatment would work.
Methodology
The study assessed the variability in 5FU concentrations and correlated them with treatment outcomes in patients receiving protracted venous infusion of 5FU.
Limitations
The study did not find a correlation between drug concentration and treatment outcomes, suggesting limitations in using drug levels to guide treatment.
Participant Demographics
Patients with advanced colorectal cancer.
Statistical Information
Confidence Interval
94 ± 25 ng ml−1 (CV = 27%)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website